Claritas Pharmaceuticals, Inc.
Other OTCTotal Valuation
Claritas Pharmaceuticals, Inc. carries a market capitalization of 3,659.00, placing it among publicly traded companies globally. Its enterprise value stands at 718,614.91, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3,659.00 |
| Enterprise Value | 718,614.91 |
Share Statistics
Claritas Pharmaceuticals, Inc. currently has 35.41M shares outstanding.
| Shares Outstanding | 35.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Claritas Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 0.00.
| PE Ratio | 0.00 |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.05 |
| P/FCF Ratio | -0.18 |
| P/OCF Ratio | -0.18 |
Enterprise Valuation
On an enterprise value basis, Claritas Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 0.93 and an EV/FCF ratio of 0.42.
| EV / Sales | N/A |
| EV / EBITDA | 0.93 |
| EV / EBIT | 0.93 |
| EV / FCF | 0.42 |
Financial Position
Claritas Pharmaceuticals, Inc. maintains a current ratio of 1.42, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.70, indicating elevated leverage, while an interest coverage ratio of 1.00 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.42 |
| Quick Ratio | 0.01 |
| Debt / Equity | 16.70 |
| Debt / EBITDA | 0.71 |
| Interest Coverage | 1.00 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -43.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -1.73 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -420,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Claritas Pharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0.000003% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached 770,000.00, while operating income came in at 770,000.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | 770,000.00 |
| Pretax Income | -4.46M |
| Net Income | -4.72M |
| EBITDA | 770,000.00 |
| EBIT | 770,000.00 |
| Earnings Per Share (EPS) | -0.13 |
Balance Sheet
Claritas Pharmaceuticals, Inc. holds 2,000.00 in cash and equivalents against 548,000.00 in total debt, resulting in a net debt position of 546,000.00. Total book value stands at -59.07M, with working capital of 3.28M providing operational flexibility.
| Cash & Cash Equivalents | 2,000.00 |
| Total Debt | 548,000.00 |
| Net Debt | 546,000.00 |
| Equity (Book Value) | -59.07M |
| Book Value Per Share | -1.84 |
| Working Capital | 3.28M |
Cash Flow
Claritas Pharmaceuticals, Inc. produced -953,000.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -953,000.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -953,000.00 |
| FCF Per Share | -0.03 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -269.97 |
| FCF Yield | -552.10 |
Stock Splits
Claritas Pharmaceuticals, Inc.'s most recent stock split took place on July 23, 2021 with a 20:1 split ratio.
| Last Split Date | 7/23/2021 |
| Split Ratio | 20:1 |
Scores
Claritas Pharmaceuticals, Inc. posts an Altman Z-Score of -6.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.90 |